![Paul Gregor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Gregor
Vorstandsvorsitzender bei Rimonyx Pharmaceuticals Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Regina Zhuk | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Miki Ben-Dor | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Orgad Laub | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Alan Lewis | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Stanley Hirsch | M | - |
Rimonyx Pharmaceuticals Ltd.
![]() Rimonyx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Israel | 5 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Paul Gregor
- Persönliches Netzwerk